"Combination of Continuous Low Doses of Vinorelbine, Cyclophosphamide and Interferon Alpha 2b ( Metronomic Chemotherapy ) for Antiangiogenic and Antivascular Effect. Trial With Pharmacodynamic Study in Adult Advanced Neoplasm"

PHASE1CompletedINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

May 31, 2006

Primary Completion Date

May 31, 2010

Study Completion Date

May 31, 2011

Conditions
Advanced Neoplasm
Interventions
DRUG

Vinorelbine, Cyclophosphamide and Interferon alpha 2b

"Level 1: Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/day; SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week.~Level 2: Oral Vinorelbine (Navelbine®)20mg x 3/week; oral Cyclophosphamide (Endoxan®) 50mg/day;SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week.~Level 3: Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/day; SC interferon alpha 2b (Introna®) 0.9 million IU x 5/week.~Level -1 (in case of toxicity at level 1): Oral Vinorelbine (Navelbine®)20mg x 2/week; oral Cyclophosphamide (Endoxan®) 50mg/every 2 days; SC interferon alpha 2b (Introna®) 0.9 million IU x 3/week ."

Trial Locations (1)

13008

Institut Paoli-Calmettes, Marseille

All Listed Sponsors
lead

Institut Paoli-Calmettes

OTHER

NCT00908869 - "Combination of Continuous Low Doses of Vinorelbine, Cyclophosphamide and Interferon Alpha 2b ( Metronomic Chemotherapy ) for Antiangiogenic and Antivascular Effect. Trial With Pharmacodynamic Study in Adult Advanced Neoplasm" | Biotech Hunter | Biotech Hunter